Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers

Disala Fernando,Richard Dimelow, Ciara Gorey, Xinyi Zhu, Catherine Muya, Connie Parker, Wayne Wright, Sara Soleman, Sarah Walsh, Madelein Crause, Georgios Vlasakakis, William Guiney,Nicola Robertson, Marylise Bergeal,Yi Cui, Alexander W Krug,Iain Uings

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY(2022)

引用 1|浏览1
暂无评分
摘要
GSK3335065 is an inhibitor of kynurenine monooxygenase (KMO) being developed for the treatment of acute pancreatitis. Healthy male volunteers were administered ascending doses of GSK3335065 or matched placebo as a single intravenous bolus injection to assess safety, tolerability, pharmacokinetics and pharmacodynamics. GSK3335065 displayed an apparent volume of distribution between 20.6 L and 44.6 L, a clearance between 0.462 L/h and 0.805 L/hr and a terminal half-life between 31.3 and 34.5 hr. In the single subject who received 1.3 mg GSK3335065, changes in tryptophan pathway metabolites were observed consistent with the changes seen in preclinical species suggesting that KMO enzyme activity was partially inhibited. However, a broad complex ventricular tachycardia was observed in this subject, which was judged to be a Serious Adverse Event (SAE) and resulted in early termination of the study. While development of GSK3335065 was subsequently discontinued, significant confounding factors hinder a clear interpretation that the tachycardia was directly related to administration of the compound.
更多
查看译文
关键词
kynurenine monooxygenase, phase 1
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要